Hostname: page-component-78c5997874-fbnjt Total loading time: 0 Render date: 2024-11-16T16:14:08.714Z Has data issue: false hasContentIssue false
  • English
  • Français

Are There Differences in Hospital Cost Between Patients With Nosocomial Methicillin-Resistant Staphylococcus aureus Bloodstream Infection and Those With Methicillin-Susceptible S. aureus Bloodstream Infection?

Published online by Cambridge University Press:  02 January 2015

Debby Ben-David ,
Ilya Novikov  and
Leonard A. Mermel
Debby Ben-David*
Affiliation:
Department of Medicine, Warren Alpert Medical School of Brown University, Providence, Rhode Island Division of Infectious Diseases, Rhode Island Hospital, Providence, Rhode Island Department of Infectious Diseases, Sheba Medical Center, Israel
Ilya Novikov
Affiliation:
Biostatistics Unit, Gertner Institute for Epidemiology and Health Policy Research, Tel Hashomer
Leonard A. Mermel
Affiliation:
Department of Medicine, Warren Alpert Medical School of Brown University, Providence, Rhode Island Division of Infectious Diseases, Rhode Island Hospital, Providence, Rhode Island
*
Department of Infectious Diseases, Sheba Medical Center, Tel Hashomer, Israel ([email protected])
Get access Rights & Permissions [Opens in a new window]

Abstract

Objective.

To examine the impact of methicillin resistance on in-hospital mortality, length of stay, and hospital cost after the onset of nosocomial Staphylococcus aureus bloodstream infection (BSI).

Design.

A retrospective cohort study.

Setting.

A tertiary care hospital in Rhode Island.

Patients.

A cohort of 182 consecutive patients who developed nosocomial BSI due to methicillin-susceptible and methicillin-resistant S. aureus (MSSA and MRSA, respectively)

Results.

Patients with MRSA BSI had a significantly longer total length of hospital and intensive care unit (ICU) stay before the onset of BSI and a higher average daily cost. Compared with ICU patients with MSSA BSI, those with MRSA BSI had a higher median total hospital cost ($42,137 vs $113,852), higher hospital cost after infection ($17,603 vs $51,492), and greater length of stay after infection (10.5 vs 20.5 days). After multivariable adjustment, ICU patients with MRSA BSI had significantly increased total hospital cost, hospital cost after infection, and length of stay after infection. However, using a propensity score approach, we found that, among ICU patients, the difference in cost after infection and the difference in length of stay after infection for MRSA, compared with MSSA BSI, were not significant. The differences among non-ICU patients who developed MRSA or MSSA BSI were not significant after multivariable adjustment or by propensity score.

Conclusions.

On the basis of propensity score, we found that methicillin resistance did not independently increase hospital cost or length of stay after onset of S. aureus BSI. We believe that use of a propensity score on a comparable subset of patients may be a better method than multivariable adjustment for assessing the impact of methicillin resistance in cohort studies.

Type
Original Articles
Information
Infection Control & Hospital Epidemiology , Volume 30 , Issue 5 , May 2009 , pp. 453 - 460
Copyright
Copyright © The Society for Healthcare Epidemiology of America 2009

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1.Diekema, DJ, Pfaller, MA, Schmitz, FJ, et al. Survey of infections due to Staphylococcus species: frequency of occurrence and antimicrobial susceptibility of isolates collected in the United States, Canada, Latin America, Europe, and the Western Pacific region for the SENTRY Antimicrobial Surveillance Program, 1997-1999. Clin Infect Dis 2001;32(Suppl 2):S114–S132.CrossRefGoogle ScholarPubMed
2.Fluit, AC, Wielders, CL, Verhoef, J, Schmitz, FJ. Epidemiology and susceptibility of 3,051 Staphylococcus aureus isolates from 25 university hospitals participating in the European SENTRY study. J Clin Microbiol 2001;39:3727–3732.CrossRefGoogle Scholar
3.Allard, C, Carignan, A, Bergevin, M, et al. Secular changes in incidence and mortality associated with Staphylococcus aureus bacteraemia in Quebec, Canada, 1991-2005. Clin Microbiol Infect 2008;14:421–428.CrossRefGoogle ScholarPubMed
4.Klevens, RM, Morrison, MA, Nadle, J, et al. Invasive methicillin-resistant Staphylococcus aureus infections in the United States. JAMA 2007;298:1763–1771.CrossRefGoogle ScholarPubMed
5.National Nosocomial Infections Surveillance (NNIS) System Report, data summary from lanuary 1992 through June 2003, issued August 2003. Am J Infect Control 2003;31:481–498.CrossRefGoogle Scholar
6.Fridkin, SK, Hill, HA, Volkova, NV, et al. Temporal changes in prevalence of antimicrobial resistance in 23 US hospitals. Emerg Infect Dis 2002;8:697–701.CrossRefGoogle ScholarPubMed
7.Cosgrove, SE, Sakoulas, G, Perencevich, EN, Schwaber, MJ, Karchmer, AW, Carmeli, Y. Comparison of mortality associated with methicillin-resistant and methicillin-susceptible Staphylococcus aureus bacteremia: a metaanalysis. Clin Infect Dis 2003;36:53–59.CrossRefGoogle ScholarPubMed
8.Whitby, M, McLaws, ML, Berry, G. Risk of death from methicillin-resistant Staphylococcus aureus bacteraemia: a meta-analysis. Med J Aust 2001;175:264–267.CrossRefGoogle ScholarPubMed
9.Kim, T, Oh, PI, Simor, AE. The economic impact of methicillin-resistant Staphylococcus aureus in Canadian hospitals. Infect Control Hosp Epidemiol 2001;22:99–104.CrossRefGoogle ScholarPubMed
10.Abramson, MA, Sexton, DI. Nosocomial methicillin-resistant and methicillin-susceptible Staphylococcus aureus primary bacteremia: at what costs? Infect Control Hosp Epidemiol 1999;20:408–411.CrossRefGoogle ScholarPubMed
11.Lodise, TP, McKinnon, PS. Clinical and economic impact of methicillin resistance in patients with Staphylococcus aureus bacteremia. Diagn Microbiol Infect Dis 2005;52:113–122.CrossRefGoogle ScholarPubMed
12.Shorr, AF, Tabak, YP, Gupta, V, Johannes, RS, Liu, LZ, Kollef, MH. Morbidity and cost burden of methicillin-resistant Staphylococcus aureus in early onset ventilator-associated pneumonia. Crit Care 2006;10:R97.CrossRefGoogle ScholarPubMed
13.McHugh, CG, Riley, LW. Risk factors and costs associated with methicillin-resistant Staphylococcus aureus bloodstream infections. Infect Control Hosp Epidemiol 2004;25:425–430.CrossRefGoogle ScholarPubMed
14.Romero-Vivas, J, Rubio, M, Fernandez, C, Picazo, JJ. Mortality associated with nosocomial bacteremia due to methicillin-resistant Staphylococcus aureus. Clin Infect Dis 1995;21:1417–1423.CrossRefGoogle ScholarPubMed
15.Soriano, A, Martinez, JA, Mensa, J, et al. Pathogenic significance of methicillin resistance for patients with Staphylococcus aureus bacteremia. Clin Infect Dis 2000;30:368–373.CrossRefGoogle ScholarPubMed
16.Garner, JS, Jarvis, WR, Emori, TG, Horan, TC, Hughes, JM. CDC definitions for nosocomial infections, 1988. Am J Infect Control 1988;16:128–140.CrossRefGoogle ScholarPubMed
17.McCabe, WR, Jackson, GG. Gram-negative bacteremia. Arch Intern Med 1962;110:83–91.Google Scholar
18.Charlson, ME, Pompei, P, Ales, KL, MacKenzie, CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987;40:373–383.CrossRefGoogle ScholarPubMed
19.Knaus, WA, Wagner, DP, Draper, EA, et al. The APACHE III prognostic system: risk prediction of hospital mortality for critically ill hospitalized adults. Chest 1991;100:1619–1636.CrossRefGoogle ScholarPubMed
20.Rubin, DB, Thomas, N. Matching using estimated propensity scores: relating theory to practice. Biometrics 1996;52:249–264.CrossRefGoogle ScholarPubMed
21.Rosenbaum, PR, Rubin, D. The central role of the propensity score in observational studies for causal effects. Biometrika 1983;70:41–55.CrossRefGoogle Scholar
22.Rubin, DB. Using propensity scores to help design observational studies: application to the tobacco litigation. Health Services and Outcomes Research Methodology 2001;2:169–188.CrossRefGoogle Scholar
23.Kurth, T, Walker, AM, Glynn, RJ, et al. Results of multivariable logistic regression, propensity matching, propensity adjustment, and propensity-based weighting under conditions of nonuniform effect. Am J Epidemiol 2006;163:262–270.CrossRefGoogle ScholarPubMed
24.Austin, PC, Mamdani, MM. A comparison of propensity score methods: a case-study estimating the effectiveness of post-AMI statin use. Stat Med 2006;25:2084–2106.CrossRefGoogle ScholarPubMed
25.Hosmer, D, Lemeshow, S. Applied logistic regression. 2nd ed. Somerset, NJ: John Wiley and Sons; 2000.CrossRefGoogle Scholar
26.Menashe, G, Borer, A, Yagupsky, P, et al. Clinical significance and impact on mortality of extended-spectrum β lactamase-producing Enterobacteriaceae isolates in nosocomial bacteremia. Scand J Infect Dis 2001;33:188–193.Google ScholarPubMed
27.Blot, SI, Vandewoude, KH, Hoste, EA, Colardyn, FA. Outcome and attributable mortality in critically 111 patients with bacteremia involving methicillin-susceptible and methicillin-resistant Staphylococcus aureus. Arch Intern Med 2002;162:2229–2235.CrossRefGoogle Scholar
28.Shay, DK, Maloney, SA, Montecalvo, M, et al. Epidemiology and mortality risk of vancomycin-resistant enterococcal bloodstream infections. J Infect Dis 1995;172:993–1000.CrossRefGoogle ScholarPubMed
29.Cosgrove, SE, Carmeli, Y. The impact of antimicrobial resistance on health and economic outcomes. Clin Infect Dis 2003;36:1433–1437.Google ScholarPubMed
30.Blot, S, Depuydt, P, Vandewoude, K, De Bacquer, D. Measuring the impact of multidrug resistance in nosocomial infection. Curr Opin Infect Dis 2007;20:391–396.CrossRefGoogle ScholarPubMed
31.Lunceford, JK, Davidian, M. Stratification and weighting via the propensity score in estimation of causal treatment effects: a comparative study. Stat Med 2004;23:2937–2960.CrossRefGoogle ScholarPubMed
32.Cosgrove, SE, Qi, Y, Kaye, KS, Harbarth, S, Karchmer, AW, Carmeli, Y. The impact of methicillin resistance in Staphylococcus aureus bacteremia on patient outcomes: mortality, length of stay, and hospital charges. Infect Control Hosp Epidemiol 2005;26:166–174.CrossRefGoogle ScholarPubMed
33.Chaix, C, Durand-Zaleski, I, Alberti, C, Brun-Buisson, C. Control of endemic methicillin-resistant Staphylococcus aureus: a cost-benefit analysis in an intensive care unit. JAMA 1999;282:1745–1751.CrossRefGoogle Scholar
34.Selvey, LA, Whitby, M, Johnson, B. Nosocomial methicillin-resistant Staphylococcus aureus bacteremia: is it any worse than nosocomial meth-icillin-sensitive Staphylococcus aureus bacteremia? Infect Control Hosp Epidemiol 2000;21:645–648.CrossRefGoogle ScholarPubMed
35.Shorr, AF, Micek, ST, Kollef, MH. Inappropriate therapy for methicillin-resistant Staphylococcus aureus: resource utilization and cost implications. Crit Care Med 2008;36:2335–2340.CrossRefGoogle ScholarPubMed
36.Khatib, R, Saeed, S, Sharma, M, Riederer, K, Fakih, MG, Johnson, LB. Impact of initial antibiotic choice and delayed appropriate treatment on the outcome of Staphylococcus aureus bacteremia. Eur J Clin Microbiol Infect Dis 2006;25:181–185.CrossRefGoogle ScholarPubMed
37.Klevens, RM, Edwards, JR, Tenover, FC, McDonald, LC, Horan, T, Gaynes, R. Changes in the epidemiology of methicillin-resistant Staphylococcus aureus in intensive care units in US hospitals, 1992-2003. Clin Infect Dis 2006;42:389–391.CrossRefGoogle ScholarPubMed